Attention Deficit Hyperactivity Disorder: Drugs

Department of Health and Social Care written question – answered at on 26 October 2023.

Alert me about debates like this

Photo of Sarah Olney Sarah Olney Liberal Democrat Spokesperson (Business, Energy and Industrial Strategy), Liberal Democrat Spokesperson (Treasury)

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure an adequate supply of (a) methylphenidate, (b) lisdexamfetamine and (c) guanfacine.

Photo of Will Quince Will Quince Minister of State (Department of Health and Social Care)

We are aware of disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD), including methylphenidate, lisdexamfetamine and guanfacine. Some issues have now been resolved. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. These issues are expected to resolve by the end of December 2023.

We understand how frustrating and distressing medicine shortages can be and we want to assure patients that we are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.

We have issued communications to the National Health Service to advise healthcare professionals on management of patients whilst there continue to be disruptions to supplies. Patients are advised to speak to their clinician regarding any concerns they have and to discuss the suitability of treatment with alternative medicines.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.